CABA — Cabaletta Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1759138 ·
Last close
$2.68
Market Cap
$436.99M
52W High
$4.23
52W Low
$2.59
ADV30
5,203,500
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -44,296,000 | -43,515,000 | 148,146,000 | 116,635,000 | 44,841,000 |
| Dec 2025 | 0 | — | -42,611,000 | -41,919,000 | 165,083,000 | 82,982,000 | 53,032,000 |
| Sep 2025 | 0 | — | -46,588,000 | -44,866,000 | 189,759,000 | 60,206,000 | 50,293,000 |
| Jun 2025 | 0 | — | -45,906,000 | -45,128,000 | 224,500,000 | 145,612,000 | 46,019,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-142,839,000
Investing CF
$1,479,000
Financing CF
$126,166,000
CapEx
$-1,229,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.27
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-560,472,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-173,082,000
Pretax Income TTM
$-175,428,000
Interest Exp TTM
$2,346,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,241,000 | -167,856,000 | 165,083,000 | 53,032,000 | — | -131,080,000 |
| Dec 2024 | 0 | -125,141,000 | -115,864,000 | 185,046,000 | 32,711,000 | — | -88,222,000 |
| Dec 2023 | 0 | -74,660,000 | -67,675,000 | 253,650,000 | 17,452,000 | — | -53,549,000 |
| Dec 2022 | 0 | -54,139,000 | -52,975,000 | 116,968,000 | 12,448,000 | — | -46,380,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.42
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | $431.69M | $8.09 | — |
| KYTX | Kyverna Therapeutics, Inc. | $443.81M | $7.30 | — |
| OCGN | Ocugen, Inc. | $416.38M | $1.23 | — |
| STRO | SUTRO BIOPHARMA, INC. | $400.51M | $24.17 | — |
| AUTL | Autolus Therapeutics plc | $396.55M | $1.49 | — |
News headlines (Yahoo Finance, 1h cache)
Kyverna Therapeutics Sinks 13%: Here’s Why
2026-07-10 19:59 · Yahoo
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup
2026-06-17 15:16 · Yahoo
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
2026-06-07 17:58 · Yahoo
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
2026-06-03 11:00 · Yahoo
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis
2026-05-21 11:42 · Yahoo
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
2026-05-20 13:40 · Yahoo
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
2026-05-18 16:00 · Yahoo
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 11:05 · Yahoo
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
2026-05-14 11:00 · Yahoo
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
2026-05-04 10:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.